Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer

Acknowledgements

This study was supported by the grant from the Research Institutions Performance Incentive Guidance Special Fund (Grant No. CSTC2022jxjl0234).

Author contributions

Huayang Pang (Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Writing—original draft), Xiufeng Chen (Data curation, Formal analysis, Investigation, Methodology, Writing—review & editing), Menghua Yan (Data curation, Investigation, Writing—review & editing) and Hao Sun (Conceptualization, Investigation, Methodology, Project administration, Supervision, Visualization, Writing—review & editing).

Supplementary data

Supplementary data is available at PCMEDI online.

Conflict of interest

None declared.

Ethics statement

Review and/or approval by an ethics committee was not needed for this study because it is a retrospective study. The patient has signed an informed consent form agreeing to share the case anonymously. This patient agreed to have an article written on his clinical course. No identifiable information was included in the article.

References

[1] Siena S, Di Bartolomeo M, Raghav K et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021;22:779-89. https://doi.org/10.1016/S1470-2045(21)00086-3.

[2] Strickler JH, Cercek A, Siena S et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 2023;24:496508. https://doi.org/10.1016/S1470-2045(23)00150-X.

[3] Benson AB, Venook AP, Adam M et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2024; 22(2D): e240029. https://doi.org/10.6004/jnccn.2024.0029.

[4] Pang HY, Yan MY, Chen XF et al. Use of trastuzumab and pertuzumab with FOLFOXIRI as neoadjuvant therapy for HER2positive resectable metastatic colorectal cancer:the first case report. Asian J Surg 2025; 48 (1): 759-61. https://doi.org/10.1016/j.asjsur.2024.07.136.

[5] Chalabi M, Verschoor YL, Tan PB et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024;390:1949-58. https://doi.org/10.1056/NEJMoa2400634.

[6] Wu ZH, Cheng Y, Hu HB et al. Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation. (In Chinese). Zhonghua Wei Chang Wai Ke Za Zhi 2024;27:416-23.

[7] Jones L, Cunningham D, Starling N. HER-2 directed therapies across gastrointestinal tract cancers-A new frontier. Cancer Treat Rev 2024;129:102789. https://doi.org/10.1016/j.ctrv.2024.102789.

[8] Cenaj O, Ligon AH, Hornick JL et al. Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma. Am J Clin Pathol 2019;152:97-108. https://doi.org/10.1093/ajcp/aqz031.

[9] Ross JS, Fakih M, Ali SM et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 2018;124:1358-73. https://doi.org/10.1002/cncr.31125.

[10] Wu Y, Chen ZQ, Gao Y et al. Progress in diagnosis and treatment of her-2 positive colorectal cancer. Chin J Colorec Dis (Electronic Edition) 2023;12:420-5.